march 19 tirzepatide will compound pharmacies stop making Important Update: Compounded No Longer Be Available After FDA says compounding pharmacies can – Health Canada approves Ozempic® Dental Diet Color:Yellow

march 19 tirzepatide will compound pharmacies stop making Important Update: Compounded No Longer Be Available After FDA says compounding pharmacies can – Health Canada approves Ozempic® Dental Diet Color:Yellow

Health Canada approves Ozempic® to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease

Søren Fjelstrup 2

Dental Diet

Color:Yellow

Injectable GLP-1s: Nearly 100% bioavailability Consistent, predictable absorption Doses of 1-2.4mg weekly for semaglutide FDA-Approved Oral Tablets: 0.4-1% bioavailability Requires 7-25mg doses to achieve similar effects Must be taken with specific timing and fasting requirements Compounded ODT Formulations: Theoretical bioavailability advantage over swallowed tablets Sublingual/buccal delivery bypasses stomach acid and first-pass metabolism However, research on peptide delivery shows challenges: peptides may be degraded by salivary enzymes, have poor permeability due to large molecular size, and face continuous wash-away from saliva No clinical trials have established actual bioavailability or effectiveness for compounded GLP-1 ODTs These formulations are not FDA-approved and haven't undergone rigorous testing The theoretical advantage of ODT formulations is that by dissolving in the mouth rather than the stomach, they could achieve better absorption than swallowed tablets while maintaining the convenience of a daily, needle-free option